This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead & Galapagos Close Research & Development Agreement
by Zacks Equity Research
Gilead (GILD) closes collaboration agreement with Galapagos, per which the latter will receive an upfront license fee payment of $3.95 billion.
The Zacks Analyst Blog Highlights: Union Pacific, Lowe's, Gilead, Target and Emerson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Union Pacific, Lowe's, Gilead, Target and Emerson
Novo Nordisk's Fiasp Gets EC Approval for Label Expansion
by Zacks Equity Research
Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
Top Research Reports for Union Pacific, Lowe's & Gilead
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including Union Pacific (UNP), Lowe's (LOW) and Gilead (GILD).
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
by Zacks Equity Research
The EMA accepts Gilead (GILD) and Galapagos' MAA for filgotinib as a treatment for rheumatoid arthritis.
Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
by Zacks Equity Research
Key highlights of the past week include collaborations, and other regulatory and pipeline news.
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Is Gilead Sciences (GILD) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Gilead Sciences (GILD) stock is a good choice for value-oriented investors right now from multiple angles.
Mergers & Acquisitions Take Center Stage in Biotech Industry
by Zacks Equity Research
Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.
Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Nektar's (NKTR) reports narrower-than expected loss in the second quarter but stock declines.
Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2019.
Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus
by Zacks Equity Research
Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.
Biotech ETFs in Focus on Impressive Q2 Earnings Results
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
Will Cost Control Help Teva (TEVA) Beat on Q2 Earnings?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q2.
Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
by Zacks Equity Research
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised
by Zacks Equity Research
Gilead (GILD) beats on Q2 earnings and sales on solid performance of the HIV franchise. The company also raises its sales guidance for the year.
Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 4.60% and 2.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Buy 6 Top Stocks Set to Beat on Earnings in Q2 Today
by Nalak Das
Second-quarter 2019 earnings expectations have improved this month. In spite of a prolonged trade conflict with China, we do not see a broad-based decline in guidance by U.S. corporates.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on top- and bottom-line numbers along with other pipeline updates, when Zoetis reports Q2 results.
Axovant (AXGT) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological diseases.
Guardant Health (GH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Guardant Health (GH) will provide updates on Guardant360 and GuardantOMNI tests during the second-quarter 2019 earnings call.
What's in Store for Array BioPharma (ARRY) in Q4 Earnings?
by Zacks Equity Research
Array BioPharma's (ARRY) Braftovi-Mektovi combination therapy is likely to drive fourth-quarter sales.